ERG and prostate cancer: Several studies by us [9] and others [10–16] have demonstrated ERG interfocal heterogeneity in 28–72 % of ERG-positive prostate cancers, and some of these also intrafocal heterogeneity in 4–42 % of ERG-positive tumor foci [9, 10, 12, 16, 17].